The “other” vasculitis syndromes and kidney involvement by Ozen, Seza
EDUCATIONAL REVIEW
The “other” vasculitis syndromes and kidney involvement
Seza Ozen
Received: 25 July 2009 /Revised: 3 September 2009 /Accepted: 3 September 2009 /Published online: 7 November 2009
# IPNA 2009
Abstract There are a number of vasculitides that are not
confined to a specific vessel size, do not have characteristic
features, and/or are not secondary to another disease. Most of
these vasculitides are rare in childhood. Behçet disease is
representativeofthisgroupasitinvolvesvesselsofanysizeon
both the arterial and venous side. In addition to renal vascular
involvement, Behçet disease may involve the kidney through
glomerulonephritis, secondary amyloidosis and, rarely, tubu-
lointerstital involvement. Vasculitis secondary to infections,
malignancy, and drugs are not common among children.
However, vasculitis may be associated with a number of
rheumatic diseases in childhood and the auto-inflammatory
syndromes (periodic fever syndromes). Auto-inflammatory
syndromes are diseases characterized by periodic attacks of
clinical and laboratory inflammation. Studies carried out
during the past decade have provided valuable information
on the mechanism of inflammation and innate immunity in
general. This group of vasculitides is associated with second-
ary amyloidosis of the kidney if not treated. Hypocomple-
mentemic urticarial vasculitis is an interesting vasculitic
disease with frequent kidney involvement. Here, we introduce
the reader to the wide scope of these diseases; although rare,
such diseases represent a challenge to the nephrologist.
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Introduction
The primary vasculitis syndromes tend to involve a specific
vessel size only and to present with a constellation of clinical
symptoms. Indeed, the primary vasculitides have been
classified both by internists and pediatricians according to
the vessel size they affect [1, 2]. However, there are a number
of vasculitides that are not classifiable within this context. In
2006, a group of pediatricians developed a working
classification for childhood vasculitides in which they
included a group of “other vasculitides”.T h i sg r o u p
represents those vasculitides that do not affect one size of
vessel only, are not secondary to another disease or factor,
and/or do not have exceptional features [2]. This paper will
review these vasculitides and the vasculitis associated
with Familial Mediterranean Fever as the prototype of
autoinflammatory diseases (Table 1).
Cogan syndrome is a rare syndrome of interstitial
keratitis and vestibuloauditory symptoms [3]. Isolated
vasculitis of the central nervous system (CNS) is charac-
terized by the involvement of the CNS vessels only.
Diagnosis is based on the demonstration of brain vessel
inflammation by angiography or, in rare cases, brain biopsy
[4]. Isolated cutaneous vasculitis is seen in patients whose
vasculitis is confined to the skin. These three diseases do
not affect the kidney—at least not as a primary target—and
will not be discussed in this paper.
Behçet Disease
Behçet Disease (BD) is a vasculitis with characteristic
features affecting both the skin and mucosa [5, 6]. It is the
only primary vasculitis that can affect vessels of all sizes
and both the arteries and veins. The vasculitis and CNS
involvement of BD are associated with considerable
morbidity and even mortality, and they need to be managed
judiciously. Behçet Disease is characterized by periods of
exacerbations and remissions [5, 6]. The presence of these
inflammatory episodes and the lack of significant autoanti-
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inflammatory disease”.
Epidemiology
Behçet Disease is a disease that is common in specific
geographic regions although a considerable number of
patients have been defined in many ethnic groups and
geographic locations. In a recent analysis from France,
BD (prevalence 7.1/100,000) was more frequent than
polyarteritis nodosa (PAN; 3/100,000), microscopic poly-
angiitis (MPA; 2.5/100 000), and Wegner's granulomatosis
(WG; 2.4/100 000) [7].
Classification
The disease is classified according to criteria proposed in
1990 [8]. These criteria require the presence of recurrent
oral ulcers and the presence of at least two of the following:
genital ulcers, eye involvement (often panuveitis), skin
lesions, and a positive pathergy test.
Clinical features
Recurrent oral ulcers have been described in all patients.
Genital ulcers, panuveitis, and skin lesions are also common
findings in children. Along with these skin and mucosal
findings, children also display the features of vasculitis, and
CNS involvement is also common [6]. Venous lesions are
characterized by thrombosis, whereas arterial lesions occur in
the form of aneurysms and stenosis [5]. Behçet Disease may
also affect the vasculature of the kidney. Based on an
extensive review of renal involvement in BD, renal involve-
ment in BD is more frequent than has been recognized,
although it is most often mild in nature [9]. In this review
renal problems have been summarized in five groups [9]:
glomerulonephritis (glomerular involvement), amyloidosis,
renal vascular involvement, tubulointerstitial involvement,
and other problems, such as side effects of drugs. Renal
amyloidosis is secondary to uncontrolled inflammation in
BD, but whether there is a causal relationship with BD and
other renal lesions is not so evident.
A metanalysis by Akpolat et al. in 2002 on kidney
involvement in BD revealed an abundance of clinical and
demographic information. The age range of patients with
glomerulonephritis was found to be 13–70 years, and the
mean interval between the time of diagnosis of BD and the
development of glomerulonephritis was 8 years (2 months
to 22 years). The glomerular disease can be silent and
detected incidentally [9]. Any type of histopathological
lesion can develop, but crescentic glomerulonephritis and
immunoglobulin (Ig)A nephropathy are probably the most
common types [10, 11].
Secondary amyloidosis has been an important complica-
tion in the past, even in childhood onset patients. AA-type
amyloid fibrils were found in all cases studied [9]. The
incidence of secondary amyloidosis has decreased with better
management of the disease. The reactive amyloidosis may be
regarded as yet another feature supporting the view that BD is
an autoinflammatory disease. Renal vascular disease is a rare
but important event in BD. The most common renal vascular
disease is renal artery aneurysm [9]. Intrarenal aneurysms,
renal artery stenosis, and renal venous thrombosis has also
been described. Hypertension is common among patients
with renal artery aneurysm or stenosis [9]. A renal disease
[amyloidosis or glomerulonephritis (GN)] or other major
vascular involvement were present in all cases with
renal vein thrombosis. Thus, especially BD patients with
nephrotic syndrome should be screened for renal venous
thrombosis. It is noteworthy that patients with vascular
involvement carried a high risk for amyloidosis, which may
reflect the association between both of these features and
significant inflammationinthe body.Finally, tubulointerstitial
lesions have been descried in BD, although they are rare [9].
Other causes, such as infections, need to be considered in
these lesions.
Treatment and management
The reader is referred to recent guidelines on the management
of BD and vascular involvement [12]. The treatment of
glomerular disease has been similar to those of the primary
kind of lesions. Steroids are indicated for the glomerulone-
phritides of BD. Additional immunosuppressives, such as
Table 1 The “other” vasculitides
1. Behçet disease
2. Vasculitis secondary to infection, malignancies, and drugs
3. Vasculitis associated with connective tissue diseases and with Familial Mediterranean Fever and other periodic fever syndromes
(autoinflammatory diseases)
4. Hypocomplementemic urticarial vasculitis
5. Cogan syndrome:
6. Isolated vasculitis of the central nervous system (CNS)
7. Isolated cutaneous vasculitis (hypersensitivity vasculitis)
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vasculitis; however, Level I evidence is lacking for the
best treatment in children. In patients with renal venous
thrombosis, most centers would use anticoagulation during
the acute phase [12]. Anticoagulation is contraindicated in
the presence of pulmonary aneurysms.
Vasculitis secondary to infection, malignancies, and drugs
There are a substantial number of published and probably
many unpublished cases of vasculitic syndromes develop-
ing in association with various infections, malignancies,
and drugs [13, 14]. In most of these cases, vasculitis is
limited to the skin, and renal involvement is rare [14]. In
our pediatric practice, infection-associated vasculitis has
been more common than vasculitis associated with malig-
nancies and drugs in children. PAN associated with
hepatitis B antigen also falls into this category since it is
an immune complex-mediated disease [15]. A few cases
have been reported in a multicenter study involving the
analysis of children with PAN [16]. Pediatric patients with
hepatitis B surface antigen (HBsAg)-associated PAN have
had renal artery aneurysms and present with hypertension
[16, 17]. Other featuresofsystemicPANmayalsobepresent.
These patients should be treated with lamivudine as antiviral
treatment plus steroid therapy, similar to that suggested in
large adult series [15]. The prognosis for patients treated in
this way is good. HBsAg-associated PAN is becoming
extinct in children, thanks to the vaccination programs.
In comparison, hepatitis C-associated cryoglobulinemic
vasculitis has not been reported in children.
The association of vasculitis with drugs is based on the
temporalrelationshipbetweenclinicallyevidentvasculitisand
the administration of the offending drugs [18]. A typical
example would be the association of propylthiouracil with
the development of antineutrophil cytoplasmic antibody
(ANCA)-associated vasculitis. The treatment of the associ-
ated disease or drug elimination will usually result in
regression of the vasculitis. In ANCA-associated vasculitis
due to drugs, the duration of immunosuppressive therapy
should be much shorter than that in primary ANCA-
associated vasculitis (AAV), and long-term maintenance
therapy may not be necessary [18].
Vasculitis associated with other diseases
Vasculitis associated with connective tissue diseases
Many rheumatic diseases are associated with vasculitis. In
adults, rheumatoid vasculitis is probably the most common
vasculitis, whereas this disease is extremely rare in
childhood. In childhood, systemic lupus erythematosus
(SLE) is the most common rheumatic disease associated with
vasculitis and kidney involvement. It is an autoimmune
disease affecting the vessels with immune complexes. A
number of renal vascular lesions can be seen in adult
patients with SLE, such as those associated with vascular
immune complex deposits and non-inflammatory necrotizing
vasculopathy[19]. The kidney may also be involved through
thrombotic microangiopathy [20], and the latter condition is
an interesting feature of SLE that is associated with
dramatic consequences. The microangiopathic lesions
result in clinical features similar to those of hemolytic
uremic syndrome [20]. Plasmapheresis is beneficial in
such cases, although controlled studies are not available
on this rare association. There has been much progress in
the treatment of SLE, especially with the introduction of
biologics, that would apply to vascular and glomerular
involvement as well.
Vasculitides associated with periodic fever syndromes
During the past decade, the autoinflammatory diseases
(AIDs) have emerged as a new chapter in the medical field.
These are a group of diseases characterized by unprovoked
inflammatory episodes and the lack of autoantibodies [21].
Most of the well-defined diseases in this group are
monogenic diseases where there is interleukin (IL)-1 over-
production [22, 23]. These diseases are of general medical
interest since they can be used to obtain information on the
mechanism of inflammation [21, 22]. They are of interest to
nephrologists since they are associated with a dramatic
kidney disease, secondary amyloidosis, that can be pre-
vented by suppressing the inflammation. The prototype of
autoinflammatory diseases is Familial Mediterranean Fever.
Familial Mediterranean Fever
Familial Mediterranean Fever (FMF) is an autoinflammatory
disease caused by mutations in the Mediterranean Fever
(MEFV)g e n e[ 21, 22] that lead to a defect in pyrin. such
mutations are associated with increased IL-1β production
a n da ne n h a n c e di n n a t ei m m u n es y s t e mr e s p o n s e[ 23].
Clinically, FMF is characterized by short attacks of fever and
serositis along with high acute phase reactants. The serositis
may manifest itself as abdominal pain (peritonitis), chest
pain (pleuritis), or arthritis. Pediatric FMF is usually
diagnosed based on criteria established for adult patients
[24]. A recently proposed set of criteria for children has been
suggested but awaits validation in multi-ethnic populations
[25].
Many researchers have focused on identifying the
clinical implications of the inflammation associated with
mutations in the MEFV gene. FMF is an autosomal
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inflammatory markers and attacks of manifest clinical
inflammation [22]. In fact, the mean erythrocyte sedimen-
tation rate and C-reactive protein levels are higher than
normal even in between attacks [26, 27]. Kidney involve-
ment in FMF may fall into one of three categories: in the
form of secondary amyloidosis, the occurrence of other
glomerulonephritides (incidental), and the association with
vasculitic lesions.
Secondary amyloidosis may occur in untreated patients.
The use of colchicine prevents the occurrence of secondary
amyloidosis and thus represents the only kidney disease
that can be prevented by an inexpensive drug [28–30].
Patients present with proteinuria only or with full-blown
nephrotic syndrome [28]. Hematuria and hypertension
almost never occur. In a multicenter study from Turkey in
which patients, both adult and pediatric, with amyloidosis
were analyzed, 32% presented with proteinuria, 40% with
nephrotic syndrome, and 28% with renal failure (n = 88)
[31]. For the patients who developed end stage renal failure,
58 were on hemodialysis, 17 were on peritoneal dialysis,
and 14 were transplanted [31]. Transplantation is the
preferred mode of treatment in patients developing end
stage renal failure. However, colchicine must be continued
at effective doses after renal transplantation otherwise
reactive amyloidosis will recur in the transplanted kidney
and other organs, including the heart [28, 31].
An increased rate of inflammatory diseases, including
vasculitides, has been noted in recent years among the
patients and carriers of MEFV mutations [27, 31]. We
initially observed in small series that certain vasculitides
had increased among these patients [27]. In a multicenter
study in Turkey involving almost 3000 patients, the highest
frequency of inflammatory diseases were PAN (0.9%),
Henoch-Schonlein purpura (HSP) (2.7%), and rheumatoid
arthritis, all higher than expected in the general population
[31].
On the other hand, we and others have reported that
among patients with certain vasculitides there is an
increased carrier rate for mutations in the MEFV gene. In
a pediatric cohort, the mutated MEFV allele frequency
among pediatric patients with rheumatic diseases, including
HSP and PAN, was significantly higher than those in
controls [27]. Gershoni-Baruch et al. [32] showed increased
MEFV mutations among children with HSP. We subsequently
showed a high carrier rate of MEFV mutations among
childhood PAN patients in Turkey [33]. All of these values
reached statistical significance. It should be noted that these
reports were from two countries with a very high carrier rate
for MEFV mutations.
Based on the results of a collaborative study with Israel,
we also suggested that patients with FMF and PAN had a
number of specific characteristic features [34]. They had
younger age of onset, with a significant number of
childhood cases. Half of the patients (8/17) reported in this
study had perirenal hematoma [34]. A striking result was
that five of the 17 patients had overlapping features of both
classic PAN affecting the mid-size artery and microscopic
PAN. All were treated with immunosuppressives in
addition to colchicine, and overall the prognosis of these
patients was good [34]. The association of vasculitis and
FMF may be simply explained by the increased inflamma-
tory milieu in patients with MEFV mutations. However, the
MEFV mutation may be acting as a susceptibility gene for
vasculitis in these multi-factorial diseases [35]. The effect
of these polymorphisms are probably mediated through the
upregulation of the innate immune system, which serves as
the initial response to the environmental trigger [35]. The
answer to the question of whether polymorphisms in the
autoinflammatory disease genes will serve as susceptibility
factors in other populations awaits more studies. These data
suggest that one needs to be aware of the possible
occurrence of these vasculitides in FMF and ensure that
proper management of the disease occurs. The other
common AIDs have been rarely associated with vasculitic
features; however, their general characteristics and kidney
involvement will also be summarized here.
Tumor necrosis factor receptor-associated periodic
syndrome
Tumor necrosis factor (TNF) receptor-associated periodic
syndrome (TRAPS) is associated with attacks of longer
duration. The attacks of fever are associated with
abdominal pain, myalgia, migratory erythematous skin
rash, conjunctivitis, and/or periorbital edema [21, 22, 36].
Amyloidosis has also been reported in these patients; 14%
of whom have developed amyloidosis to date [21]. Thus,
urinalysis needs to be checked at each visit. Amyloidosis
has been associated with cysteine substitutions in the
protein [21, 36]. Anti-TNF treatment is used to suppress
the inflammation. Etanercept is the preferred treatment
since caution has been suggested for the use of infliximab
in TRAPS patients [37].
Hyperimmunoglobulinemia D with periodic fever syndrome
Hyperimmunoglobulinemia D with periodic fever syndrome
(HIDS) is an autosomal recessively inherited periodic fever
syndromecausedbymutationsintheMVK gene, which codes
for the enzyme mevalonate kinase [38, 39]. The majority of
the patients reported to date are from The Netherlands and
France. However, cases have been reported worldwide. The
fever is commonly accompanied by abdominal pain, diarrhea,
vomiting, and cervical lymphadenopathy [38, 39]. There has
been only one case of amyloidosis. Although the risk of
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quality of life in their early years. Crescentic GN has been
reported in a patient with HIDS; however, the causal
association was unclear [40].
There is currently a lack of solid evidence for the
treatment of HIDS. Anti-TNF and anti-IL-1 treatment has
been reported to be effective in recent studies [39].
CIAS-1-pathies—the cryopyrin-associated periodic fever
syndromes
These include:
Familial cold autoinflammatory syndrome (FCAS);
Muckle-Wells syndrome (MWS);
Neonatal-onset multi-system inflammatory disease
[NOMID, also known as chronic infantile neurologic
cutaneous articular (CINCA) syndrome].
These three syndromes are associated with mutations in
cryopyrin [41–43]. All are characterized by fevers and a
nonpruritic, urticarial rash that usually presents in infancy
(later in MWS). They may have some of the overlapping
features described above [41–43]. FCAS presents with
attacks precipitated by cold, as suggested in the name [42].
The main differentiating feature of MWS is the hearing
defect [41]. NOMID/CINCA represents the most severe
form of the three and is associated with neurological defects
and more persistent features [43]. All are associated with
the development of secondary amyloidosis mainly affecting
the kidney, if inflammation is not suppressed. Anti-IL1
treatment is the mainstay of treatment, and it is hoped that
this treatment will prevent the reactive amyloidosis.
Hypocomplementemic urticarial vasculitis syndrome
Hypocomplementemic urticarial vasculitis syndrome
(HUVS), first described in the early 1970s, is very rare in
the pediatric population. However, it must be considered in
the differential diagnosis for patients with glomerulone-
phritis, urticarial rash, arthralgias/arthritis, and pulmonary
disease [44]. HUVS is a rare autoimmune disease charac-
terized by recurrent urticaria and low complement levels. In
1982, these two features were designated as the major
criteria, with the suggestion that at least two minor criteria
are also required for the diagnosis of HUVS [45]. These
minor criteria are venulitis on skin biopsy, arthritis, ocular
inflammation, abdominal pain, positive C1q antibodies, and
glomerulonephritis. The binding of C1q antibodies to
immune complexes is thought to be important in the
pathogenesis of renal disease in HUVS [44]. Indeed, C1q
antibodies are probably present in all patients. Half of the
patients develop glomerulonephritis. Various types of renal
lesions may be observed: mesangial proliferative lesions,
focal proliferative, membranoproliferative, and membra-
nous lesions have been reported [46]. No specific therapy is
currently available for HUVS. Patients have been treated
with steroids and various immunosuppressives [46]. It is
the experience of the author and others that crescentic
glomerulonephritis is particularly aggressive and difficult to
treat in patients with HUVS. The presence of high levels of
ANA and positivity of anti-double stranded DNA Ab are
exclusion factors for the disease [44]. However, a portion of
patients may progress to full-blown SLE. The patients
should be thus screened appropriately.
Conclusion
The vasculitides reported here are relatively rare diseases in
the common practice of pediatric nephrologists. However,
they have remarkable features that are of interest. They also
shed light on our understanding of other common diseases.
Awareness of the features of these vasculitides will allow
for an earlier diagnosis of the problem and better
management.
Questions
(Answers appear following the reference list)
1. Which is true for Behçet disease?
a. It is never seen in children
b. It is a short lasting mucositis
c. Only mid-size arteries are affected
d. Both the veins and arteries may be affected
e. CNS is not involved
2. What kind of kidney involvement is seen in Behçet
disease?
a. Glomerulopathies
b. Secondary amyloidosis
c. Tubulointerstitial disease
d. Renal artery aneurysm
e. All of the above
3. Autoinflammatory diseases lack autoantibodies. Is this
statement:
a. True
b. False
4. In FMF patients who are not sufficiently treated what
kind of kidney disease develops?
a. Tubulointerstitial nephritis due to colchicine
b. Microscopic polyarteritis/polyangiitis
c. Secondary amyloidosis
d. An immune complex nephritis
e. IgA nephropathy
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which is false?
a. There is hypocomplementemia
b. There is persistent urticaria
c. Anti C1q antibodies are detected
d. Half develop glomerulonephritis
e. Patients have cryoglobulins
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